ArticleNPJ vaccines2026
An oral Eimeria-vectored vaccine induces protective immunity against chicken infectious anemia.
Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Effective mucosal vaccines are critical for controlling infectious diseases in poultry, yet limitations in antigen delivery systems hinder their development. Here, we present a transgenic Eimeria tenella platform engineered to express multicopy viral capsid protein 1 (VP1) and viral capsid protein 2 (VP2) antigens of chicken infectious anemia virus (CIAV), a major immunosuppressive pathogen in poultry. Using a quadripartite co-transfection system driven by high-activity promoters, we achieved stable integration and expression of heterologous antigens, confirmed via PCR and Western blotting. Fluorescence-assisted cell sorting increased the proportion of recombinant parasites to >90%. Despite modestly reduced fecundity, the engineered strain (Et-TetVP1VP2) retained immunogenicity and induced robust humoral and cellular immune responses in vivo. Oral immunization of chickens conferred protection, reducing viral load and pathological lesions upon CIAV challenge. This work establishes E. tenella as a promising oral vaccine vector, offering a scalable and cost-effective platform for antigen delivery against avian pathogens, with broader implications for mucosal vaccine design.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.